Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)
China flag China · Delayed Price · Currency is CNY
6.80
+0.05 (0.74%)
Aug 4, 2026, 3:04 PM CST

Xiangxue Pharmaceutical Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Revenue
1,5291,5951,8592,2992,1872,971
Revenue Growth
-10.65%-14.16%-19.16%5.13%-26.38%-3.30%
Gross Profit
425.11422.89407.61743.33533.38741.4
Operating Income
-71.1-102.06-233.9249.67-175.35-22.39
Net Income
-1,416-1,392-858.56-388.96-530.06-688.47
Earnings Per Share
-2.16-2.11-1.30-0.59-0.80-1.04
EPS Growth
------

Revenue by Segment

Fiscal YearFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '24 Dec '23 Jan '23 Jan '22
Pharmaceutical Manufacturing
430.57302.7825.29384.52475.2
Pharmaceutical Distribution
75.61252.4360.36588.12868.86
Medical Instruments
1920.0917.4216.214.8
Others
357.75347.37351.47273.85170.5
Chinese Herbal Medicines
990.74936.1744.75924.371,209
Offset of Business Segment
-278.26----
Total
1,5951,8592,2992,1872,971

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Investments
144.74254.57144.74149.32166.63367.17
Total Debt
1,4371,4672,2432,4332,4583,448
Net Cash (Debt)
-1,292-1,212-2,098-2,284-2,291-3,081
Net Cash Growth
------
Net Cash Per Share
-1.97-1.84-3.18-3.46-3.46-4.65

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Cash Flow
156.09139.6318.17263.44227.38257.56
Capital Expenditures
-19.99-21.51-35.24-56.03-367.27-562.74
Free Cash Flow
136.09118.12-17.07207.41-139.89-305.18
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Gross Margin
27.81%26.51%21.93%32.33%24.39%24.96%
Operating Margin
-4.65%-6.40%-12.58%2.16%-8.02%-0.75%
Pretax Margin
-88.14%-83.79%-45.31%-16.92%-23.40%-21.40%
Profit Margin
-92.63%-87.26%-46.19%-16.92%-24.24%-23.18%
FCF Margin
8.90%7.40%-0.92%9.02%-6.40%-10.27%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Forward PE
-11.9311.9311.9311.9311.93
P/FCF Ratio
33.0450.95-16.42--
PS Ratio
2.943.773.481.481.811.77